To support an HTA assessment of a diagnostic device for use outside hospitals, we developed an economic assessment and submission dossier addressing GP collaboration, training, and pricing uncertainties.
Economic modelling
We offer outstanding expertise in economic modelling, led by our highly experienced directors.
Our approach is rooted in working with clients and external stakeholders to thoroughly understand the disease process, the treatment landscape and the clinical and health system value of your technology. Together with our deep knowledge of modelling techniques and health technology assessment, this ensures our models help maximise your chances of successful reimbursement.
Cost-effectiveness and budget impact models
We help you find the right modelling techniques for your particular decision problem – whether state transition, partitioned survival, microsimulation or discrete event simulation models. Budget impact models can be stand-alone or incorporated into the cost-effectiveness model. We can create interactive budget impact models for use in payer negotiations.Early modelling to improve decision-making
Our web-based interactive early model is a powerful addition to your decision-making tool kit. Early economic modelling can help inform stop-go decisions, commercial planning and evidence generation planning during the development pipeline.
- Explore value drivers and critical sensitivities using different scenarios, inputs and assumptions – even with limited data
- Define the likely pricing corridor
- Share insights with internal stakeholders with the user-friendly interface
Pricing models
- Analyse pricing scenarios to define your economically justifiable pricing corridor
- Explore the financial implications of innovative pricing solutions such as indication-specific pricing, financial-based risk sharing and performance-based risk sharing agreements.
- Use with payers during pricing negotiations.
Case studies
We optimised a cost-effectiveness model that initially lacked resonance and failed to demonstrate cost-effectiveness.
We developed a comprehensive market access strategy to support HTA and reimbursement submissions for a product with a unique mode of action, whose benefits were only partially reflected in clinical trials.
